Paice Kelli, Tang Girdwood Sonya, Mizuno Tomoyuki, Pavia Kathryn, Punt Nieko, Tang Peter, Dong Min, Curry Calise, Jones Rhonda, Gibson Abigayle, Vinks Alexander A, Kaplan Jennifer
Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Pediatr Crit Care Med. 2024 Dec 1;25(12):1103-1116. doi: 10.1097/PCC.0000000000003599. Epub 2024 Aug 20.
To determine the frequency of early meropenem concentration target attainment (TA) in critically ill children with severe sepsis; to explore clinical, therapeutic, and pharmacokinetic factors associated with TA; and to assess how fluid resuscitation and volume status relate to early TA.
Retrospective analysis of prospective observational cohort study.
PICU in a single academic quaternary care children's hospital.
Twenty-nine patients starting meropenem for severe sepsis (characterized as need for positive pressure ventilation, vasopressors, or ≥ 40 mL/kg bolused fluid), of which 17 were newly escalated to PICU level care.
None.
Concentration-time profiles were analyzed using modeling software employing opportunistic sampling, Bayesian estimation, and a population pharmacokinetic model. Time above four times minimum inhibitory concentration (T > 4×MIC), using the susceptibility breakpoint of 1 µg/mL, was determined for each patient over the first 24 hours of meropenem therapy, as well as individual clearance and volume of distribution (Vd) estimates. Twenty-one of 29 patients met a target of 40%T > MIC 4 μg/mL. Reaching TA, vs. not, was associated with lower meropenem clearance. We failed to identify a difference in Vd or an association between the TA group and age, weight, creatinine-based estimated glomerular filtration rate (eGFR), or the amount of fluid administered. eGFR was, however, negatively correlated with overall T > MIC.
Eight of 29 pediatric patients with early severe sepsis did not meet the selected TA threshold within the first 24 hours of meropenem therapy. Higher clearance was associated with failure to meet targets. Identifying patients likely to have higher meropenem clearance could help with dosing regimens.
确定严重脓毒症危重症患儿早期美罗培南浓度达标(TA)的频率;探索与TA相关的临床、治疗和药代动力学因素;并评估液体复苏和容量状态与早期TA的关系。
对前瞻性观察队列研究的回顾性分析。
一家单一的学术性四级儿童专科医院的儿科重症监护病房(PICU)。
29例因严重脓毒症开始使用美罗培南治疗的患者(特征为需要正压通气、血管活性药物或≥40 mL/kg的液体冲击量),其中17例为新升级至PICU级护理的患者。
无。
使用采用机会性采样、贝叶斯估计和群体药代动力学模型的建模软件分析浓度-时间曲线。在美罗培南治疗的前24小时内,为每位患者确定高于四倍最低抑菌浓度(T>4×MIC)的时间(使用1 μg/mL的药敏折点),以及个体清除率和分布容积(Vd)估计值。29例患者中有21例达到了40%T>MIC 4 μg/mL的目标。与未达到TA相比,达到TA与较低的美罗培南清除率相关。我们未能发现Vd存在差异,也未发现TA组与年龄、体重、基于肌酐的估计肾小球滤过率(eGFR)或给予的液体量之间存在关联。然而,eGFR与总体T>MIC呈负相关。
29例早期严重脓毒症儿科患者中有8例在美罗培南治疗的前24小时内未达到选定的TA阈值。清除率较高与未达到目标相关。识别可能具有较高美罗培南清除率的患者有助于制定给药方案。